Dr. Secord on the Role of PARP Inhibitors in Ovarian Cancer

Video

Angeles Alvarez Secord, MD, gynecologic oncologist, Duke Cancer Center, discusses the role of PARP inhibitors in ovarian cancer based on their current indications in the treatment landscape.

Angeles Alvarez Secord, MD, gynecologic oncologist, Duke Cancer Center, discusses the role of PARP inhibitors in ovarian cancer based on their current indications in the treatment landscape.

The role of PARP inhibitors is quite expansive, Secord says. There are indications for PARP inhibitors in the frontline setting with BRCA1/2 somatic or germline mutations, as well as in all-comers with platinum-sensitive disease, regardless of biomarker status.

Each of the PARP inhibitors available have specific indications as well. For example, rucaparib (Rubraca) is indicated for the treatment of patients with BRCA1/2-mutant ovarian cancer, Secords says.

<<< View more from the 2020 SGO Winter Meeting

Related Videos
Michael Richardson, MD
Gottfried Konecny, MD
Patrick I. Borgen, MD
Gottfried E. Konecny, MD, lead clinician, gynecologic oncology, Department of Medicine, the University of California, Los Angeles
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine